Cholecystitis Clinical Trial
Official title:
Efficacy Of Near Infrared Incisionless Fluorescent Cholangiography (NIFC) During Laparoscopic Cholecystectomy
The Study is designed to compare the effectiveness of Near Infrared Fluorescence Cholangiography (NIFC) to standard white light imaging (WLI) in visualizing and identifying the main biliary and hepatic structures (Cystic Duct, Right Hepatic Duct, Common Hepatic Duct, Common Bile Duct, Cystic-CBD junction, Cystic-Gallbladder junction and any Accessory Ducts) during laparoscopic cholecystectomy. The aim is to demonstrate that NIFC performs better than standard white light (WLI) alone in visualizing and identifying extra-hepatobiliary structures (Cystic Duct, Right Hepatic Duct, Common Hepatic Duct, Common Bile Duct, Cystic-CBD junction, Cystic-Gallbladder junction, and any Accessory Ducts) before and after dissection during Laparoscopic Cholecystectomy (LC).
Recently, a novel technique to visualize structures using fluorescent light and intravenous
dye has been developed.
Near Infrared Incisionless Fluorescent Cholangiography (NIFC) is a medical imaging technique
that uses fluorescence to detect properly labeled structures during surgery.
NIFC is performed using imaging devices with the purpose of providing real-time simultaneous
information from color reflectance images (white light) and fluorescence emission (near
infrared light). One or more light sources are used to excite and illuminate the sample.
Light is collected using optical filters that match the emission spectrum of the fluorophore.
Imaging lenses and digital cameras are used to produce the final image.
During laparoscopic cholecystectomies, the visualization of the extra-hepatic bile ducts with
fluorescence is called Near Infrared Incisionless Fluorescent Cholangiography (NIFC).
Fluorescence equipment and a dye are necessary in order to perform a NIFC, but the technique
requires no radiation or incision. A fluorescence dye is administrated intravenously at least
45 minutes before the surgery, which is excreted by the liver and the bile duct The Study is
designed to compare the effectiveness of Near Infrared Fluorescence Cholangiography (NIFC) to
standard white light imaging (WLI) in visualizing and identifying the main biliary and
hepatic structures (Cystic Duct, Right Hepatic Duct, Common Hepatic Duct, Common Bile Duct,
Cystic-CBD junction, Cystic-Gallbladder junction and any Accessory Ducts) during laparoscopic
cholecystectomy.
Eligible patients will be identified through clinical and test evaluation. Eligibility will
be verified by the patient's primary surgeon. The surgeon will determine the indication and
date of the surgery. Once a patient is confirmed as eligible, the surgeon will introduce the
study in detail. If after being introduced to the study and having had the opportunity to ask
questions, the patient is willing to participate, he/she will be asked to review and sign the
informed consent document .
Upon entry in the clinical trial patients will be randomly allocated to the intervention arm.
Data will be collected at enrolment time, during surgery, at the end of surgery and one week
after surgery.
Upon entry in the clinical trial, the master study database (REDCap, will randomly allocated
patients to one of the study arms (1:1) within site (1:1) using a computer generated random
sequence. This will provide an allocation sequence for each site. Once a patient is enrolled
and a database file in REDCap is initiated for that patient, he/she will be assigned
electronically to one of the study arms.
Patient will be blind to the intervention but surgeon blinding will not be feasible due to
the nature of the intervention. The study will involve a considerable number of surgeons in
each site, which should compensate any potential bias of some of them in favor or against
either approach.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03636841 -
Reduction of Operating Time by a Smoke Electroprecipitation Device for Acute Cholecystitis
|
N/A | |
Completed |
NCT02379780 -
Ultrasound Guided Subcostal Transversus Abdominis Plane Versus Paravertebral Block in the Laparoscopic Cholecystectomy
|
N/A | |
Completed |
NCT02264444 -
Establishing Visualization Grading Scale on LESS Cholecystectomy
|
N/A | |
Completed |
NCT02461147 -
Prospective Validation of "Cholecystectomy First" Strategy for Gallstone Migration
|
||
Completed |
NCT01937104 -
ONSD According to the Position During Laparoscopy
|
N/A | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Completed |
NCT00746850 -
Harmonic in Laparoscopic Cholecystectomy for Acute Cholecystitis
|
N/A | |
Completed |
NCT00940264 -
Laparoscopic Transvaginal Hybrid Cholecystectomy: a Prospective Data Collection.
|
N/A | |
Completed |
NCT00370344 -
Small-incision Open Cholecystectomy or Laparoscopic Cholecystectomy for Gallbladder Disease
|
Phase 2/Phase 3 | |
Completed |
NCT00195351 -
Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection
|
Phase 4 | |
Completed |
NCT02858986 -
3D Versus 4K Laparoscopic Cholecystectomy
|
N/A | |
Completed |
NCT04602156 -
US-guided Trocar Versus Seldiger Technique for Percutaneous Cholecystostomy
|
N/A | |
Completed |
NCT04942665 -
Low Dose ICG for Biliary Tract and Tumor Imaging
|
Phase 2 | |
Completed |
NCT02547064 -
Effect of Modified Stylet Angulation on the Intubation With GlideScope®
|
N/A | |
Completed |
NCT00230971 -
Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)
|
Phase 4 | |
Completed |
NCT04122261 -
A Clinical Study of Chinese Domestic Surgical Robot
|
N/A | |
Completed |
NCT04716166 -
Incentive Spirometry and Upper Abdominal Laparoscopic Surgery
|
N/A | |
Completed |
NCT01476319 -
Improving Informed Consent Process for Percutaneous Cholecystostomy in the Emergency Department
|
N/A | |
Withdrawn |
NCT02225418 -
Transmuscular Quadratus Lumborum Block for Laparoscopic Cholecystectomy
|
N/A | |
Suspended |
NCT04306939 -
Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
|